Stockreport

Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates

Longboard Pharmaceuticals, Inc.  (LBPH) 
PDF Bexicaserin (LP352) Phase 1b/2a PACIFIC Study positive topline data in participants with Developmental and Epileptic Encephalopathies (DEEs) was reported in JanuaryAnnou [Read more]